AVEO Pharmaceuticals Initiates First Clinical Trial Of Novel HGF Antagonist In Patients With Advanced Solid Tumors And Lymphomas
AVEO Pharmaceuticals, Inc., announced that it has initiated a Phase 1 clinical trial to evaluate the safety, tolerability and recommended dose of SCH900105 (AV-299), its novel, highly potent antibody to hepatocyte growth factor (HGF), administered intravenously in patients with relapsed or refractory solid tumors or lymphoma. SCH900105 (AV-299) is being developed in collaboration with Schering-Plough (NYSE: SGP).
